Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Small cell lung cancer PDX model response to LSD1 inhibitor RG6016/ORY1001

ABSTRACT: Small cell lung cancer PDX model response to LSD1 inhibitor RG6016/ORY1001

PROVIDER: PRJNA400180 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5975650.fastq.gz	Fastqsanger.gz
	SRR5975660.fastq.gz	Fastqsanger.gz
	SRR5975670.fastq.gz	Fastqsanger.gz
	SRR5975651.fastq.gz	Fastqsanger.gz
	SRR5975661.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Comparison of small cell lung cancer PDX model FHSC04 for response to LSD1 inhibitor RG6016/ORY1001

Project description:The goal of this study was to understand how the LSD1 inhibitor RG6016/ORY1001 leads to selective efficacy in subsets of small cell lung cancer. SCLC cell lines, PDX models studied ex vivo and studied in vivo were employed in this analysis

2019-06-10 | GSE103096 | GEO

Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001

2019-06-10 | GSE103095 | GEO

RNA-seq of small intestinal organoids treated with an inhibitor for the epigenetic modifier LSD1

Project description:To assess the role of LSD1 in mice small intestinal epithelium, small intestinal organoids were treated with an inhibitor for LSD1 (GSK-LSD1) and compared to untreated organoids. Similar to intestinal epithelium from mice with an intestinal epithelium specific LSD1-KO, paneth cells dissappear upon GSK-LSD1 treatment. We used these sequencing data to show that these small intestinal organoids have a similar phenotype as mice epithelium without LSD1.

2020-11-16 | E-MTAB-9077 | biostudies-arrayexpress

Small cell lung cancer PDX model response to LSD1 inhibitor RG6016/ORY1001

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-06-10 | GSE103097 | GEO

Effects of loss of LSD1 activity on small cell lung cancer cell lines via pharmacological inhibition

Project description:To investigate the effects of loss of LSD1 (KDM1A) on differential gene expression, we treated two cell lines of small cell lung cancer with 1 M LSD1 inhibitor ORY-1001 or vehicle control for 10 days. We then performed gene expression profiling analysis on treated and control cells for each of the two cell lines.

2022-06-13 | GSE205880 | GEO

Human small intestinal organoids grown with a specific protocol to enrich for Paneth cells were treated with an inhbitor (GSK-LSD1) for the epigenetic modulator LSD1.

Project description:To assess the role of LSD1 in human intestinal epithelium, human small intestinal organoids were treated with an inhibitor for LSD1 (GSK-LSD1) and compared to untreated organoids. The organoids were grown with specific conditions where Paneth cells are present in the organoids as similar experiments in mice show that Paneth cells disappear upon GSK-LSD1 treatment. Similar to mouse intestinal organoids, Paneth cells dissappear upon GSK-LSD1 treatment. Furthermore, we used these gene set enrichment analysis on these microarray data to show that these human intestinal organoids have a similar phenotype as mice epithelium without LSD1.

2020-11-16 | E-MTAB-7863 | biostudies-arrayexpress

Effect of BET bromodomain inhibitor and/or mTOR inhibitor on transcriptome of small cell lung cancer patient-derived xenograft LX95 tumors

Project description:We report mTOR inhibitor (mTORi) is synergistic with BET inhibitor (BETi) in controlling tumor growth and inducing apoptosis in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. In this study, we studied impact of different treatment on whole-genome mRNA transcriptome in SCLC PDX tumors. Four different treatments (vehicle control, NHWD870 [BETi; 1.5mg/kg], everolimus [mTORi; 2mg/kg], and the combo [NHWD870 1mg/kg and everolimus 1.5mg/kg] were administered daily for one week in a small cell lung cancer PDX LX-95 model. Tumor cells were isolated from PDX tumors using a magnetic-activated cell sorting method to enrich human tumor cells and total RNA was extracted using the RNeasy Mini Kit (Qiagen). mRNA libraries were constructed and pair-ended sequenced using Illumina high-throughput sequencing technology. The length of sequence reads was 150 bp.The samples have 12 to 129 million pass filter reads with more than 90% of bases above the quality score of Q30. We found BET inhibitor increases expression of RPS6KA2, a gene that mediates crosstalk between MAPK and mTOR pathway.

2020-09-01 | GSE155923 | GEO

LSD1 inhibitor T-3775440 inhibits SCLC cell proliferation by disrupting LSD1 interactions with SNAG domain proteins INSM1 and GFI1B

Project description:T-3775440 is an irreversible inhibitor of the chromatin demethylase LSD1. Here we describe the anti-cancer effects and mechanism of action of T-3775440 in small cell lung cancer (SCLC). T-3775440 inhibited proliferation of SCLC cells in vitro and retarded SCLC tumor growth in vivo. Our results argue that LSD1 plays an important role in neuroendocrine-associated transcription and cell proliferation of SCLC via interactions with the SNAG domain proteins INSM1 and GFI1B. Targeting these critical interactions with LSD1 inhibitors offers a novel rational strategy to therapeutically manage SCLC.

2018-02-01 | GSE100169 | GEO

Trophoblast stem cells (TSC) global transcriptome in stemness conditions after treatment with Lsd1 inhibitor or induction of Lsd1 depletion [RNA-seq]

Project description:RNA-Seq for Lsd1-deficient TSCs or treated with Lsd1 inhibitor for 24hrs

2017-06-12 | GSE78781 | GEO

Brown adipocyte differentiation modulation by LSD1 inhibitor

Project description:Brown adipocyte differentiation modulation by LSD1 inhibitor

| PRJNA301795 | ENA